

CS/BSE/ AFR/BOOK-CL
August 14, 2012

TO
THE MANAGER
LISTING DEPARTMENT
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA, BANDRA KURLA COMPLEX
BANDRA (E), MUMBAI – 400 051

Dear Sir/Madam,

Stock Code – 530239

- Sub:** 1) Notification of Audited Financial Results for the financial year ended 31st March 2012 – Clause 41
2) Notification of Un-Audited Financial Results for the Quarter ended 30/06/2012– Clause 41
3) Dividend Recommendation – Clause 20
4) Closure of Register of Members & Share Transfer Books - Clause-16

.....
1) Notification of Audited Financial Results for the financial year ended 31st March 2012-Clause 41 and other information

We are forwarding here with Audited Financial Results for the financial year 2011-2012, in the prescribed Proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Annual Audited financial results for the financial year 2011-2012 in its meeting held today i.e. 14th August, 2012.

2) Notification of Un-Audited Financial Results for the Quarter ended 30/06/2012 Clause 41

We are forwarding here with Un-Audited Financial Results of our Company for three months ended 30th June 2012, in the prescribed Proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-Audited results for the first quarter in its meeting held on 14th August 2012 and Limited Review Report of Auditors of the Company.



Page | 1

SUVEN Life Sciences Limited

Corporate Office: 10th Floor, 100 Feet Road # 9, Avenue 1, Durgam Cheruvu, Hyderabad - 500033

Branch Office: 10th Floor, 100 Feet Road # 9, Avenue 1, Durgam Cheruvu, Hyderabad - 500033

Info@suven.co.in

www.suven.co.in

Brief Financials as required to be furnished under clause 20 are as follows:

(Rs in lakhs)

Particulars		2011-12	2010-11
(i).	Revenue from operations	20420.78	15043.39
(ii).	Operating expenditure	18106.14	13688.62
(iii).	Depreciation and amortization	599.79	544.55
(iv).	Operating profit	1714.86	810.22
(v).	Interest expense	990.93	610.52
(vi).	Other income	190.25	125.75
(vii).	Profit before Tax	914.18	325.44
(viii).	Provision for Tax	(522.06)	(714.50)
(ix).	Profit for the year	1436.24	1039.95
(x).	Balance brought forward from previous year	2825.93	1764.81
(xi).	Profit available for appropriation	4262.17	2804.76
	Appropriations:		
(xii).	Proposed final dividend	350.20	291.82
(xiii).	Tax on dividend	56.81	47.34
(xiv).	Difference in final dividend plus tax (09-10)	0.04	1.97
(xv).	Transfer to General Reserve	150.00	110.00
(xvi).	Balance carried to balance sheet	3705.12	2353.62

2) Dividend Recommendation – Clause 20

The Board of Directors in its meeting held today i.e. 14th August, 2012, has also recommended Dividend Re 0.30 paise per equity share of face value of Re 1/- each (30%) for the financial year ended 31/03/2012 the dividend will be paid on and from 12th October, 2012, subject to the approval of Members in ensuing Annual General Meeting.

3) Closure of Register of Members & Share Transfer Books - Clause-16

Pursuant to clause 16 of the Listing agreement, we hereby notify the Book Closure dates for the Register of members and Share Transfer as under.



Security Code	Type of Security & Paid-up value	Book-Closure		Purpose
		From	To	
SUVEN	Equity Shares Rs 1.00 each	19/09/2012	21/09/2012 (both days inclusive)	AGM & Dividend Declaration

The Annual General Meeting of the Company will be held on Thursday the 27th day of September 2012

Please find enclosed Press release of our company. We request you to take these Documents on your Records.

Thanking You,

Yours faithfully,

For **SUVEN LIFE SCIENCES LIMITED**



K HANUMANTHA RAO
Company Secretary



Going beyond Commitment



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034
UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 th JUNE 2012


PART - I		Rs. in Lacs			
Sl. No.	PARTICULARS	Quarter Ended			Previous Year Ended
		30/6/2012	31/03/2012	30/06/2011	31/3/2012
		Unaudited	Un-audited	Unaudited	Audited
1	Income from operations				
	(a) Net sales/income from operations (Net of excise duty)	7,052.72	6,289.42	4,463.29	20,420.78
	(b) Other operating income	-	-	-	-
	Total income from operations (net)	7,052.72	6,289.42	4,463.29	20,420.78
2	Expenses				
	a) Cost of materials consumed	2,144.63	2,487.22	1,854.11	8,145.56
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	330.84	418.09	(10.62)	(564.74)
	d) Employee benefits expense	651.73	633.69	495.16	2,283.03
	e) Depreciation and amortisation expense	183.23	182.78	138.73	599.79
	f) Other expenses - Manufacturing Exps	848.55	791.31	554.07	2,667.83
	- Selling Exps	100.21	43.86	48.41	216.91
	- Administrative Exps	517.42	607.50	257.24	1,704.57
	- R & D Exps	874.68	821.77	747.82	3,304.91
	- Provision for MTM on Forward Contracts	250.96	(854.63)	-	348.06
	Total expenses	5,902.25	5,131.59	4,084.92	18,705.92
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	1,150.47	1,157.83	378.37	1,714.86
4	Other Income	52.47	12.52	20.28	190.25
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	1,202.94	1,170.35	398.65	1,905.11
6	Finance costs	321.92	420.86	163.58	990.93
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	881.02	749.49	235.07	914.18
8	Exceptional Items	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 ± 8)	881.02	749.49	235.07	914.18
10	Tax Expenses	84.68	34.91	(101.02)	(522.06)
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)	796.34	714.58	336.09	1,436.24
12	Extraordinary Items (net of tax expense ₹ ____ Lakhs)	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11 ± 12)	796.34	714.58	336.09	1,436.24
14	Share of profit / (loss) of associates*	-	-	-	-
15	Minority interest *	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *				
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1,167.32 Re. 1.00	1,167.32 Re. 1.00	1,167.32 Re. 1.00	1,167.32 Re. 1.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				11,584.83
19.i	Earning Per Share (EPS) (before extraordinary items) (of ₹ Rs.1/- each) (not annualised):				
	a) Basic	0.68	0.61	0.29	1.23
	b) Diluted	0.68	0.61	0.29	1.23
19.ii	Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):				
	a) Basic	0.68	0.61	0.29	1.23
	b) Diluted	0.68	0.61	0.29	1.23

PART - II		30/6/2012	31/03/2012	30/06/2011	31/3/2012
A	PARTICULARS OF SHAREHOLDING	Unaudited	Un-audited	Unaudited	Audited
1	Public share holdings - Number of shares - Percentage of Share holding	42,679,160 36.56%	42,679,160 36.56%	42,858,960 36.72%	42,679,160 36.56%
2	Promoters and promoter group Shareholding** a) Pledged / Encumbered - Number of shares - Percentage of Shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company) b) Non-Encumbered - Number of shares - Percentage of Shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company)	NIL NIL NIL 74,052,828 100.00% 63.44%	NIL NIL NIL 74,052,828 100.00% 63.44%	NIL NIL NIL 73,873,028 100.00% 63.28%	NIL NIL NIL 74,052,828 100.00% 63.44%
Particulars		3 months ended (30/06/2012)			
8	INVESTOR COMPLAINTS Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter	0 20 20 0			

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED					Rs. In Lacs
	PARTICULARS	Quarter Ended			Year Ended
		30/6/2012	31/03/2012	30/06/2011	31/3/2012
		Unaudited	Unaudited	Unaudited	Audited
1	SEGMENT REVENUE :- a) Manufacturing (CRAMS) b) Services (DDDSS) c) Research & Development Net Sales from Operations	6,514.95 537.77 - 7,052.72	5,921.54 367.88 - 6,289.42	4,305.07 158.22 - 4,463.29	19,168.87 1,251.91 - 20,420.78
2	SEGMENT RESULTS :- Profit/(Loss) before tax and interest: a) Manufacturing (CRAMS) b) Services (DDDSS) c) Research & Development TOTAL Less: i) Interest ii) Other Un-allocable exps net off un-allocable Income Total Profit Before Tax	2,494.37 231.20 (874.68) 1,850.89 298.14 671.73 881.02	1,646.42 134.84 (821.77) 959.49 318.43 (108.43) 749.49	1,327.31 68.55 (747.82) 648.04 163.58 249.39 235.07	6,507.91 531.83 (3,304.91) 3,734.83 888.50 1,932.15 914.18
3	CAPITAL EMPLOYED (Segment Assets - Segment Liabilities) a) Manufacturing (CRAMS) b) Services (DDDSS) c) Research & Development d) Net assets which are not segmented and used commonly TOTAL	11,483.10 3,131.68 2,525.28 1,564.05 18,704.11	10,704.10 3,298.34 2,228.26 2,023.90 18,254.60	11,276.13 712.73 3,513.00 3,494.93 18,996.79	10,704.10 3,298.34 2,228.26 2,023.90 18,254.60

- Notes: 1) The above un-audited results were approved and taken on record at the Board of Directors' meeting held on 14th Aug'12
2) Previous years figures have been regrouped / reclassified whenever necessary.
3) The limited review has been completed by the Statutory Auditors.
4) Provision for MTM Losses pertain to Forward Contracts entered for covering the future receivables in USD.
5) Suven Nishta pharma pvt ltd, the 100% subsidiary, has been merged wef 1 st Jan 2012 and accordingly the results have been prepared. Hence the current year's figures are not comparable with the previous year figures.
6) The figures of the last quarter of the previous year are the balancing figures between the audited figures for the full financial year and the published 'year to date figures' upto the third quarter.
7) The Board has recommended a Dividend of Re.0.30 per Equity share (i.e.30% of face value of Rs.1/- each) for the year 2011-12, subject to approval of the shareholders in the ensuing Annual General Meeting.
8) The variation in net profits between audited results as on 31/03/2012 to the unaudited results declared on 4/5/2012 is on account of merger of Suven Nishta pharma pvt ltd (100% subsidiary) w e f 1 st Jan 2012.

Place : Hyderabad
Date : 14th Aug'2012

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & CEO

We Deliver



Ref No.LR/005/2012-13:

LIMITED AUDIT REVIEW REPORT

To

The National Stock Exchange Limited
Mumbai.

We have reviewed the accompanying statement of unaudited financial results of M/S. SUVEN LIFE SCIENCES LIMITED, having registered office at 8-2-334, 6th Floor, SDE Serene Chambers, Road No 7, Banjara Hills, Hyderabad – 34, for the period ended on 30.06.2012, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for KARVY & CO.,
Chartered Accountants
(Registration No.001757S)


(K. AJAY KUMAR)
P A R T N E R
M.No.21989



Place: Hyderabad
Date : 14.08.2012.

Suven Life Sciences

News Release

Suven's PAT up by 137 % & Turnover up by 58% for 1st Quarter ended 30th June' 2012

HYDERABAD, INDIA (14 Aug 2012) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its un-audited financial results for the quarter ended 30th June 2012. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Aug, 2012 at Hyderabad.

Financial Highlights for the 1th Quarter ended June 2012:

Growth in revenue	Rs 711 mil vs. Rs 448 mil	- Up by 58 %
Growth in PAT	Rs 80 mil vs. Rs 34 mil	- Up by 137 %
Growth in EBIDTA	Rs 138 mil vs. Rs 54 mil	- Up by 158 %

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 85 mil (12.31 % on revenue) for the quarter ended June' 2012.

The Board has recommended a Dividend of Re 0.30 per share (30% of face value of Rs.1 each) for the accounting year 2011-12 subject to the approval in AGM.

*PAT for the Qtr ending June 2012 is after provision for MTM of Rs. 25.10 mil towards forward contracts due to exchange fluctuation

The Hon'ble High Court of Andhra Pradesh has sanctioned the Scheme of Amalgamation of Suven Nishtaa Pharma Private Limited with Suven Life Sciences Limited and order of High Court has been filed with Registrar of Companies, Andhra Pradesh, Hyderabad

During the quarter there were major qualitative achievements with the grant of 8 (eight) product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

